Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Dental Caries Clinical Trial

Official title:

A Phase 2, Double-Blind, Placebo-Controlled and Open-Label Multi-Center Study to Evaluate the Microbiology and Safety of C16G2 Administered in Multiple Oral Gel Doses to Adult and Adolescent Dental Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02594254
• Other study ID #: C3J15-203-00
• Status: Completed
• Phase: Phase 2
• Start date: November 2015
• Est. completion date: September 2016

Study information

• Verified date: July 2019
• Source: Armata Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if C16G2 Gel administered over a certain period of time either with a toothbrush or a custom dental tray can effectively kill bacteria in the mouth that cause dental cavities.

Description:

This multi-center, multiple-arm study will evaluate the microbiological activity and safety of C16G2 Gel in male and female dental subjects, 12 to 75 years of age. The study will be conducted in a randomized, double-blind, placebo-controlled and open-label manner and enroll adolescent (12-17 years of age) and adult subjects (18-75 years of age).

A total of approximately 128 study subjects will be enrolled into up to 7 study arms. Study drug (C16G2 Gel or Placebo) will be administered via manual brush gel application (MBGA) or tray gel application (TGA). Two C16G2 concentrations will be evaluated. Four study arms will be conducted in a double blind manner, with a treatment allocation ratio of 4:1 (C16G2:Placebo), three study arms will be conducted in an open-label manner. Before dosing, eligible subjects will undergo professional dental prophylaxis on Day 0. Clinic visits for all study arms will include Visit 1 (Screening/Days -21 to 0), and a varying number of dosing and follow-up visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 135
• Est. completion date: September 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Males and females, 12-75 years of age, inclusive, at the time the Assent and/or Informed Consent Form is signed

2. Female subjects of childbearing potential, defined as not surgically sterile or at least two (2) years postmenopausal, must agree to use one of the following forms of contraception from screening through the last study visit: hormonal (oral, implant, or injection) begun >30 days prior to screening; barrier (condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive options may also include abstinence, relationship with same sex partner or partner who has had a vasectomy at least six (6) months prior to the screening visit

3. Male subjects only: willing to use contraception or abstain from sexual activity beginning with the first exposure to study drug and continuing until discharged from the study due to completion or Early Termination

4. Healthy, as determined by the Investigator (in consultation with the Medical Monitor, as needed), based on medical and dental history, concurrent illnesses, laboratory results, concomitant medications, oral cavity assessment, and targeted physical examination (extraoral, head and neck) during Screening Note: Subjects on a stable dose of medication may be eligible for screening and will be assessed by the Medical Monitor on a case-by-case basis.

5. Have a minimum of 12 bicuspids and molars with a minimum of 8 molars and bicuspids NOT having restorations, crowns, sealants

6. Demonstrated ability to expectorate =2 mL of stimulated saliva in 5 minutes

7. Have a salivary S. mutans of 1.0 x 10^5 colony forming units (CFUs)/mL or greater at Screening using mitis salivarius-bacitracin (MSB) agar plating

8. Willing to refrain from using non-study dentifrice and other non-study oral care products (oral care rinses, fluoride products, etc.) during the study

9. Willing to postpone elective dental procedures (e.g., dental cleanings) between Screening and final post-treatment visit (End of Study or Early Termination)

10. Willing and able to comply with oral hygiene and diet instructions

11. Has dentition adequate for custom dental tray gel application

12. Able to understand and sign the Assent and/or Informed Consent Form prior to initiation of study procedures

13. Able to communicate with the Investigator/study center personnel, understand and comply with the study requirements, and willing to return for protocol-specified visits at the appointed times

Exclusion Criteria:

1. Advanced periodontal disease

2. Active caries lesion(s) within 30 days prior to study drug administration (confirmed by comprehensive caries examination including standard radiographs if deemed necessary by the Investigator) Note: Subjects presenting with insipient, non-cavitated lesion(s) are not excluded

3. Medical condition (e.g., artificial heart valve, history of infective endocarditis, cardiac transplant with valvular dysfunction, congenital heart disease or total joint replacement) for which antibiotics are recommended prior to dental visits and/or procedures

4. Pathologic lesions of the oral cavity (suspicious or confirmed)

5. Full dentures or orthodontic appliances, e.g., braces; Note: partial dentures, removable retainers and night guards are not excluded, provided that they are cleaned regularly throughout the duration of the study.

6. Use of systemic antibiotics, topical oral antibiotics, or use of other drugs, which in the opinion of the Investigator could influence the study outcome, within 30 days prior to Screening and throughout the entire study.

7. Medical history indicating the woman is pregnant, breastfeeding/lactating or has a positive urine pregnancy test

8. Participation in a clinical trial or receipt of a non-FDA approved therapy within 30 days prior to study drug administration (depending on the specifics, participation in an observational study is not necessarily excluded)

9. Prior participation in a C16G2 clinical trial and known to have received C16G2 active gel or mouth rinse Note: Placebo subjects are not excluded

10. Presence of any condition or concurrent illness, which in the opinion of the Investigator, would compromise normal immune function (e.g., diabetes, rheumatoid arthritis, lupus, liver disease, organ transplant, etc.), interfere with the use of study dentifrice and oral care products, or interfere with the ability to comply with study requirements, or jeopardize the safety of the subject or the validity of the study results

Related Conditions & MeSH terms

• Dental Caries

Intervention

Drug:
• C16G2 Gel
Antimicrobial peptide

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Tufts University	Boston	Massachusetts
United States	Texas Baylor College of Dentistry	Dallas	Texas
United States	East Carolina University	Greenville	North Carolina
United States	Imperial Beach Family Dentistry	Imperial Beach	California
United States	Indiana University School of Dentistry	Indianapolis	Indiana
United States	Anthony Henegar, DDS, PA	Irving	Texas
United States	John F. Pittaway, DMD	Kalispell	Montana
United States	Plaza West II Dental Group	Kalispell	Montana
United States	New York University College of Dentistry	New York	New York
United States	University of Pennsylvania School of Dental Medicine	Philadelphia	Pennsylvania

Sponsors (4)

Lead Sponsor	Collaborator
Armata Pharmaceuticals, Inc.	Agility Clinical, Inc., SynteractHCR, Vantage Data Designs, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antimicrobial Activity of C16G2	To assess the targeted antimicrobial activity of C16G2 Gel applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque	Evaluated over up to 5 months
Primary	Total Oral Bacterial Levels	Total bacterial levels will be evaluated by measuring cfu/ml counts of salivary and plaque bacteria	Evaluated 7 days post last study drug administration
Primary	Safety of C16G2 Gel Administrations assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events	Safety will be assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events	Up to 7 days post last study drug administration